Table 2.
Clinical activity targeting TIGIT.
| Trial name/ identifier | Phase | Indication | ⍺TIGIT Fc | ⍺TIGIT group | Control Group | ORR | PFS (months) | OS (months) | > grade 3 AE | sponsor | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ⍺TIGIT | control | ⍺TIGIT | control | ⍺TIGIT | control | ⍺TIGIT | control | |||||||
| Tiragolumab Combinations | ||||||||||||||
| CITYSCAPE-02 (NCT03563716) | 2 | NSCLC (PD-L1 pos., 1%) | active Fc | tiragolumab (⍺TIGIT) + atezolizumab (⍺PD-L1) | atezolizumab (⍺PD-L1) | 31.30% | 16.20% | 5.4 | 3.6 | 23.2 | 14.5 | 21% | 18% | Genentech/ Roche |
| SKYSCRAPER-01 (NCT04294810) | 3 | NSCLC (PD-L1 high) | active Fc | tiragolumab (⍺TIGIT) + atezolizumab (⍺PD-L1) | atezolizumab (⍺PD-L1) | 2° endpoint | 1° endpoint, not met | 1° endpoint | 64.4%a | 64.2%a | ||||
| SKYSCRAPER-02 (NCT04256421) | 3 | SCLC | active Fc | tiragolumab (⍺TIGIT) + atezolizumab (⍺PD-L1) | atezolizumab (⍺PD-L1) | similar | 5.4a | 5.6a | 13.6a | 13.6a | 33.3%a | 27.5%a | ||
| MORPHEUS-liver (NCT04524871) | 1b/2 | Hepatocellular Carcinoma | active Fc | tiragolumab (⍺TIGIT) + atezolizumab (⍺PD-L1) + bevacizumab (⍺VGEF-A) | atezolizumab (⍺PD-L1) + bevacizumab (⍺VGEF-A) | 42.5%a | 11.1%a | 11.1a | 4.2a | immature | 33.3%a | 27.5%a | ||
| Summary of other ongoing trials | 2–3 | Hepatocellular, renal and esophageal squamous cell carcinoma; gastric, rectal, and urothelial cancer; HNSCC | active Fc | tiragolumab (⍺TIGIT) +/− atezolizumab (⍺PD-L1) or ⍺Lag-3/PD-1 bispecific in combinationn with ⍺VGEF-A or chemo | single arm or the same combination without tiragolumab (⍺TIGIT) | |||||||||
| Domvanalimab Combinations | ||||||||||||||
| ARC-7 (NCT04262856) | 2 | NSCLC (PD-L1 high) | Fc silent | domvanalimab (⍺TIGIT) + zimberelimab (⍺PD-1) +/− etrumadenant (A2R Ant) | zimberelimab (⍺PD-1) | 40%/44%a | 30%a | 9.3/9.9a | 5.4a | immature | 47%/52%a | 58%a | Gilead/ Arcus | |
| Summary of other ongoing trials | 2–3 | NSCLC, melanoma, gastrointestinal tract adenocarcinoma | Fc silent | domvanalimab (⍺TIGIT) + zimberelimab (⍺PD-1) +/− chemo | zimberelimab (⍺PD-1) +/− chemo or single arm | |||||||||
| Vibostolimab Combinations | ||||||||||||||
| KEYVIBE-002 (NCT04725188) | 2 | NSCLC (metastatic) | active Fc | vibostolimab (⍺TIGIT) + pembrolizumab (⍺PD-1) +/− docetaxel (DXL) | docetaxel | 29.9% (6.0% w/o DXL) | 15.3% | 5.6 (2.7 w/o DXL) | 3.2 | 10.2 (7.5 w/o DXL) | 8.8 | 29.4% (20.5% w/o DXL) | 12% | Merck |
| Summary of other ongoing trials | 2–3 | NSCLC, SCLC, melanoma, hematological and solid tumors | active Fc | vibostolimab (⍺TIGIT) + pembrolizumab (⍺PD-1) alone or in combinationn with chemo, radio or other cancer therapies | single arm or the same combination without vibostolimab (⍺TIGIT) | |||||||||
Table includes detailed information on trials targeting TIGIT that have reported results. Additional trials targeting TIGIT that are recruiting patients or ongoing but have not reported results are summarized for each antibody. Additional trials in phase 2 or higher by iTeos/GSK, BMS, Astra Zeneca, and BeiGene are listed on ClinicalTrails.gov.
a
interim results